Ken Griffin Fulcrum Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 115,700 shares of FULC stock, worth $411,892. This represents 0.0% of its overall portfolio holdings.
Number of Shares
115,700
Previous 52,800
119.13%
Holding current value
$411,892
Previous $498,000
43.98%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding FULC
# of Institutions
138Shares Held
53.9MCall Options Held
4.17MPut Options Held
515K-
Ra Capital Management, L.P. Boston, MA10.2MShares$36.4 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$18.7 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$17.1 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$17 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$11.7 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $185M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...